[{"id":"2f9874c4-f677-4e33-b8c8-e0765095f8b3","acronym":"DUAL-OV-CAR-NK","url":"https://clinicaltrials.gov/study/NCT07480954","created_at":"2026-03-28T01:39:31.330Z","updated_at":"2026-03-28T01:39:31.330Z","phase":"Phase 1/2","brief_title":"Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)","source_id_and_acronym":"NCT07480954 - DUAL-OV-CAR-NK","lead_sponsor":"Beijing Biotech","biomarkers":" FOLR1 • MSLN • MUC16","pipe":"","alterations":" ","tags":["FOLR1 • MSLN • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/04/2026","start_date":" 02/04/2026","primary_txt":" Primary completion: 02/17/2027","primary_completion_date":" 02/17/2027","study_txt":" Completion: 05/17/2028","study_completion_date":" 05/17/2028","last_update_posted":"2026-03-18"},{"id":"9c52b3ba-74cb-41b4-9ef2-03d1ced908cf","acronym":"IMGN151-1001","url":"https://clinicaltrials.gov/study/NCT05527184","created_at":"2024-02-01T02:20:14.331Z","updated_at":"2025-02-25T12:28:59.108Z","phase":"Phase 1","brief_title":"First in Human Study of IMGN151 in Recurrent Gynaecological Cancers","source_id_and_acronym":"NCT05527184 - IMGN151-1001","lead_sponsor":"AbbVie","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e opugotamig olatansine (IMGN-151)"],"overall_status":"Recruiting","enrollment":" Enrollment 423","initiation":"Initiation: 01/11/2023","start_date":" 01/11/2023","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2025-02-24"},{"id":"01487ba7-9d61-4bb2-b7ab-9b09a185d399","acronym":"","url":"https://clinicaltrials.gov/study/NCT06609928","created_at":"2025-02-25T14:43:34.775Z","updated_at":"2025-02-25T14:43:34.775Z","phase":"Phase 1","brief_title":"FH-FOLR1 Chimeric Antigen Receptor T Cell Therapy for Treating Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia","source_id_and_acronym":"NCT06609928","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 03/12/2025","start_date":" 03/12/2025","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2042","study_completion_date":" 10/01/2042","last_update_posted":"2025-02-14"},{"id":"96f0f596-bee1-42fc-9dcc-41fcf8f78f40","acronym":"SL03-OHD-105","url":"https://clinicaltrials.gov/study/NCT05483933","created_at":"2022-08-02T12:55:49.417Z","updated_at":"2025-02-25T15:27:30.695Z","phase":"Phase 1","brief_title":"Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers","source_id_and_acronym":"NCT05483933 - SL03-OHD-105","lead_sponsor":"Shattuck Labs, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • SL-172154"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 02/07/2025","primary_completion_date":" 02/07/2025","study_txt":" Completion: 02/07/2025","study_completion_date":" 02/07/2025","last_update_posted":"2025-02-11"},{"id":"809acd3d-0f20-4fcc-9b3f-5f01fafa10a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05456685","created_at":"2022-07-13T12:56:36.433Z","updated_at":"2025-02-25T17:31:27.306Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05456685","lead_sponsor":"AbbVie","biomarkers":" FOLR1 • BRCA","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 125","initiation":"Initiation: 09/28/2022","start_date":" 09/28/2022","primary_txt":" Primary completion: 05/12/2026","primary_completion_date":" 05/12/2026","study_txt":" Completion: 05/12/2026","study_completion_date":" 05/12/2026","last_update_posted":"2025-01-30"},{"id":"cd892406-57e9-4ba5-95af-1d838d031b7c","acronym":"CA116-001","url":"https://clinicaltrials.gov/study/NCT05613088","created_at":"2023-12-07T21:16:29.597Z","updated_at":"2025-02-25T13:36:17.948Z","phase":"Phase 2","brief_title":"A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT05613088 - CA116-001","lead_sponsor":"Bristol-Myers Squibb","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • topotecan • farletuzumab ecteribulin (MORAb-202)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 06/05/2024","primary_completion_date":" 06/05/2024","study_txt":" Completion: 10/11/2026","study_completion_date":" 10/11/2026","last_update_posted":"2024-11-21"},{"id":"73e3eec7-4518-48c4-b46f-3dd2b5e30704","acronym":"","url":"https://clinicaltrials.gov/study/NCT03835819","created_at":"2021-01-18T18:56:17.574Z","updated_at":"2025-02-25T16:08:53.728Z","phase":"Phase 2","brief_title":"A Phase 2 Study of Mirvetuximab Soravtansine (IMGN853) and Pembrolizumab in Endometrial Cancer (EC)","source_id_and_acronym":"NCT03835819","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" FOLR1 • MLH1 • MSH6 • MSH2","pipe":" | ","alterations":" MSH6 expression","tags":["FOLR1 • MLH1 • MSH6 • MSH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSH6 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/02/2020","start_date":" 01/02/2020","primary_txt":" Primary completion: 06/04/2024","primary_completion_date":" 06/04/2024","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2024-11-08"},{"id":"14077522-c4f9-49b8-a790-5ed5d6ceade7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04928612","created_at":"2025-03-03T15:59:29.814Z","updated_at":"2025-03-03T15:59:29.814Z","phase":"Phase 1","brief_title":"A Study of CBP-1018 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04928612","lead_sponsor":"Coherent Biopharma (Suzhou) Co., Ltd.","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBP-1018"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 11/04/2021","start_date":" 11/04/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-08-28"},{"id":"1191eb18-5a65-4cb1-bbf7-bb4841595232","acronym":"","url":"https://clinicaltrials.gov/study/NCT03832361","created_at":"2025-02-26T08:44:50.615Z","updated_at":"2025-02-26T08:44:50.615Z","phase":"Phase 2","brief_title":"Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-α Positive Endometrial Cancer","source_id_and_acronym":"NCT03832361","lead_sponsor":"Alessandro Santin","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 07/15/2020","start_date":" 07/15/2020","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-08-20"},{"id":"5e4a1b0f-c052-4ea3-b52c-56f571a546e9","acronym":"KEYNOTE PN409","url":"https://clinicaltrials.gov/study/NCT02606305","created_at":"2024-02-04T01:25:14.975Z","updated_at":"2024-07-02T16:34:25.701Z","phase":"Phase 1/2","brief_title":"Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer","source_id_and_acronym":"NCT02606305 - KEYNOTE PN409","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Completed","enrollment":" Enrollment 264","initiation":"Initiation: 03/02/2016","start_date":" 03/02/2016","primary_txt":" Primary completion: 03/12/2021","primary_completion_date":" 03/12/2021","study_txt":" Completion: 03/12/2021","study_completion_date":" 03/12/2021","last_update_posted":"2024-06-14"},{"id":"023cf6d7-38d4-4089-89bb-ebee230e66e8","acronym":"GLORIOSA","url":"https://clinicaltrials.gov/study/NCT05445778","created_at":"2022-07-06T15:54:42.215Z","updated_at":"2024-07-02T16:34:26.631Z","phase":"Phase 3","brief_title":"Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)","source_id_and_acronym":"NCT05445778 - GLORIOSA","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1 • BRCA • MUC16","pipe":" | ","alterations":" FOLR1 expression • MUC16 elevation","tags":["FOLR1 • BRCA • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • MUC16 elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 418","initiation":"Initiation: 12/27/2022","start_date":" 12/27/2022","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2024-06-13"},{"id":"80a15019-c76b-402b-869e-abfd7ab973d5","acronym":"PRO1184-001","url":"https://clinicaltrials.gov/study/NCT05579366","created_at":"2022-10-13T16:56:38.872Z","updated_at":"2024-07-02T16:35:06.017Z","phase":"Phase 1/2","brief_title":"PRO1184 for Advanced Solid Tumors","source_id_and_acronym":"NCT05579366 - PRO1184-001","lead_sponsor":"ProfoundBio US Co.","biomarkers":" HER-2 • FOLR1","pipe":" | ","alterations":" HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • FOLR1 expression • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • carboplatin • Rina-S (rinatabart sesutecan)"],"overall_status":"Recruiting","enrollment":" Enrollment 374","initiation":"Initiation: 12/07/2022","start_date":" 12/07/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-05-03"},{"id":"85edd770-3ac8-453d-88dc-75e0a0a175d3","acronym":"PICCOLO","url":"https://clinicaltrials.gov/study/NCT05041257","created_at":"2021-09-13T15:55:27.708Z","updated_at":"2024-07-02T16:35:08.475Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)","source_id_and_acronym":"NCT05041257 - PICCOLO","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1 • BRCA","pipe":" | ","alterations":" FOLR1 expression • BRCA mutation","tags":["FOLR1 • BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 79","initiation":"Initiation: 08/31/2021","start_date":" 08/31/2021","primary_txt":" Primary completion: 01/17/2024","primary_completion_date":" 01/17/2024","study_txt":" Completion: 12/13/2024","study_completion_date":" 12/13/2024","last_update_posted":"2024-04-22"},{"id":"95fe996a-08c8-4bbd-9a80-6d6d99bc679d","acronym":"REFRaME-O1","url":"https://clinicaltrials.gov/study/NCT05870748","created_at":"2023-05-23T16:06:11.980Z","updated_at":"2024-07-02T16:35:08.676Z","phase":"Phase 2/3","brief_title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","source_id_and_acronym":"NCT05870748 - REFRaME-O1","lead_sponsor":"Sutro Biopharma, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression • FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression • FOLR1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • paclitaxel • pegylated liposomal doxorubicin • topotecan • luveltamab tazevibulin (STRO-002) • Neulasta (pegfilgrastim)"],"overall_status":"Recruiting","enrollment":" Enrollment 600","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-04-19"},{"id":"bd7ac170-f9ec-4021-bd06-e5f2697c1c6d","acronym":"ELU-FRα-1","url":"https://clinicaltrials.gov/study/NCT05001282","created_at":"2021-08-11T14:55:40.694Z","updated_at":"2024-07-02T16:35:12.374Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)","source_id_and_acronym":"NCT05001282 - ELU-FRα-1","lead_sponsor":"Elucida Oncology","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELU001"],"overall_status":"Recruiting","enrollment":" Enrollment 166","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-03-28"},{"id":"a012529c-d433-4cc1-950b-b069e61ba45c","acronym":"MIROVA","url":"https://clinicaltrials.gov/study/NCT04274426","created_at":"2021-01-18T20:45:40.588Z","updated_at":"2024-07-02T16:35:23.352Z","phase":"Phase 2","brief_title":"Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer","source_id_and_acronym":"NCT04274426 - MIROVA","lead_sponsor":"AGO Research GmbH","biomarkers":" BRCA1 • BRCA2 • FOLR1 • MUC16","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • BRCA wild-type","tags":["BRCA1 • BRCA2 • FOLR1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • BRCA wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • doxorubicin liposomal"],"overall_status":"Recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 10/13/2021","start_date":" 10/13/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-01-15"},{"id":"d152c3ba-cce4-4f26-ae10-9617725a91a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05378737","created_at":"2023-12-22T17:17:42.298Z","updated_at":"2024-07-02T16:35:25.446Z","phase":"Phase 1","brief_title":"Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of BAT8006 for Injection","source_id_and_acronym":"NCT05378737","lead_sponsor":"Bio-Thera Solutions","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 216","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-12-22"},{"id":"437a0b30-c17c-4f59-99bc-c3201c096d92","acronym":"","url":"https://clinicaltrials.gov/study/NCT05830097","created_at":"2023-04-26T14:04:47.548Z","updated_at":"2024-07-02T16:35:26.556Z","phase":"Phase 1/2","brief_title":"A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05830097","lead_sponsor":"Coherent Biopharma (Hefei) Co., Ltd.","biomarkers":" FOLR1 • TRPV6","pipe":"","alterations":" ","tags":["FOLR1 • TRPV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CBP-1019"],"overall_status":"Recruiting","enrollment":" Enrollment 260","initiation":"Initiation: 03/14/2023","start_date":" 03/14/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-12-12"},{"id":"7ea7b76e-29f6-4753-a54f-be730ae868af","acronym":"MIRASOL","url":"https://clinicaltrials.gov/study/NCT04209855","created_at":"2021-01-18T20:30:11.495Z","updated_at":"2024-07-02T16:35:54.021Z","phase":"Phase 3","brief_title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression","source_id_and_acronym":"NCT04209855 - MIRASOL","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 453","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 09/01/2023","primary_completion_date":" 09/01/2023","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2023-03-06"},{"id":"9be2dc89-a060-4c39-916d-51ddaf88fadd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05622890","created_at":"2022-11-21T14:57:00.361Z","updated_at":"2024-07-02T16:36:00.129Z","phase":"Phase 3","brief_title":"A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05622890","lead_sponsor":"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.","biomarkers":" FOLR1 • MUC16","pipe":"","alterations":" ","tags":["FOLR1 • MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 08/18/2022","start_date":" 08/18/2022","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2022-11-21"},{"id":"792ef6e7-2868-41af-bc38-cd9bdc2aa080","acronym":"","url":"https://clinicaltrials.gov/study/NCT02317705","created_at":"2022-06-22T16:54:35.197Z","updated_at":"2024-07-02T16:36:08.532Z","phase":"Phase 2","brief_title":"Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer","source_id_and_acronym":"NCT02317705","lead_sponsor":"On Target Laboratories, LLC","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 positive"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 12/01/2014","start_date":" 12/01/2014","primary_txt":" Primary completion: 11/01/2015","primary_completion_date":" 11/01/2015","study_txt":" Completion: 11/01/2015","study_completion_date":" 11/01/2015","last_update_posted":"2022-06-21"},{"id":"7dbbc938-f2df-43be-869e-296694ec3653","acronym":"","url":"https://clinicaltrials.gov/study/NCT02593227","created_at":"2021-01-18T12:35:08.510Z","updated_at":"2024-07-02T16:36:27.756Z","phase":"Phase 2","brief_title":"Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer","source_id_and_acronym":"NCT02593227","lead_sponsor":"Marker Therapeutics, Inc.","biomarkers":" HER-2 • FOLR1","pipe":" | ","alterations":" FOLR1 expression","tags":["HER-2 • FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • TPIV200 • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 07/15/2021","primary_completion_date":" 07/15/2021","study_txt":" Completion: 07/15/2021","study_completion_date":" 07/15/2021","last_update_posted":"2021-07-19"},{"id":"ab1ca9de-5568-498f-b59d-7da3aaee923b","acronym":"IMGN-0401","url":"https://clinicaltrials.gov/study/NCT01609556","created_at":"2021-02-17T19:52:44.463Z","updated_at":"2024-07-02T16:36:34.499Z","phase":"Phase 1","brief_title":"First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Mirvetuximab Soravtansine in Adults With Ovarian Cancer and Other Folate Receptor 1 (FOLR1)-Positive Solid Tumors","source_id_and_acronym":"NCT01609556 - IMGN-0401","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1","pipe":"","alterations":" ","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Elahere (mirvetuximab soravtansine-gynx)"],"overall_status":"Completed","enrollment":" Enrollment 206","initiation":"Initiation: 06/28/2012","start_date":" 06/28/2012","primary_txt":" Primary completion: 03/19/2018","primary_completion_date":" 03/19/2018","study_txt":" Completion: 03/19/2018","study_completion_date":" 03/19/2018","last_update_posted":"2021-02-17"},{"id":"6ea69e56-9836-479f-95d8-b31e44da4f12","acronym":"FORWARD I","url":"https://clinicaltrials.gov/study/NCT02631876","created_at":"2021-01-18T12:47:56.060Z","updated_at":"2024-07-02T16:36:40.091Z","phase":"Phase 3","brief_title":"A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer","source_id_and_acronym":"NCT02631876 - FORWARD I","lead_sponsor":"ImmunoGen, Inc.","biomarkers":" FOLR1","pipe":" | ","alterations":" FOLR1 positive","tags":["FOLR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FOLR1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • topotecan • doxorubicin liposomal"],"overall_status":"Completed","enrollment":" Enrollment 366","initiation":"Initiation: 03/02/2016","start_date":" 03/02/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 01/01/2020","study_completion_date":" 01/01/2020","last_update_posted":"2020-10-14"}]